No Data
No Data
Guggenheim Maintains Tourmaline Bio(TRML.US) With Buy Rating
Tourmaline Bio Stock Slides 7% Amid News of CMO's Departure
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
Tourmaline Bio's Chief Medical Officer Resigns Amicably
Express News | Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
No Data
No Data